LEAPMOTOR
25.4.2022 09:02:07 CEST | Business Wire | Press release
On February 25, 2022, Leapmotor for the first time announced the highlights of its new model C01. It is an electric mid-to-large-sized sedan developed on its C-Vehicle Platform, and also the first mass production model equipped with CTC battery technology, acceleration to 100 km/h in less than 4 seconds, 5-meter plus length and 700km ultra-long range. It will also further expand the portfolio with a planned launch in Q2 of 2022.
Technological and Natural Aesthetics to Create an Inner "Style"
Leapmotor C01 takes natural aesthetics as the design concept, emphasizing smart mobility experience. The design of C01 is featured with technical elements, offering a comfortable environment while the immersive cabin brings a luxurious experience for young, high-end, urban families.
C01 Key Product Features Unveiled
Because of Leapmotor's full-suite of R&D capabilities, the C01 offers compelling features – CTC technology, acceleration, vehicle length and NEDC range. It is set to become a popular product on the EV market.
NO.1 – Leapmotor’s First Mass Production Model with CTC Technology
CTC (Cell-To-Chassis) is a cutting-edge technology that integrates battery into the chassis, leading to greater shock resistance and improved strength of the vehicle. The C01 offers better handling performance, range and collision safety thanks to the CTC Technology.
0-100 km/h Acceleration in less than 4 seconds — Fastest acceleration among electric sedans within the same class in China, supercar-level performance
Leapmotor C01 has one of the fastest acceleration among electric sedans within the same class in China. It is equipped with "Higher Dimension" intelligent power system, using variable-structured oil-cooled electric drive with up to 1 million kilometers lifespan and the world's top NVH performance and power efficiency, meeting the demand for long range and high performance of EVs. In addition, flush door handle, sportback design, 0.226 ultra-low drag coefficient and 5% reduced vehicle weight will offer better performance.
Vehicle Length of over 5 Meter — Mid-to-large-sized sedan
As a mid-to-large sedan, Leapmotor C01 has a 5-meter plus length, wider rear legroom and large trunk space, offering exceptional comfort.
700km Ultra-long NEDC Range — Meeting long-distance travel needs
The C01 is equipped with a 90kWh ultra-large battery, capable of 700km ultra-long NEDC range, meeting consumer needs for long-distance travel. With penetrated large module scheme and intelligent battery management system can improve battery life, range and overall safety.
Full-suite of R&D capabilities Empowering Innovation
Leapmotor has been committed to growing its portfolio of R&D capabilities, obtaining and declaring 1,474 patents, 939 of which have been approved, and more than 40% of which are innovation patents.
Leapmotor increased its product line in 2021 by releasing the C11 as a mid-sized smart electric SUV, entering the RMB 150,000-200,000 SUV sector that has long been dominated by automakers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005242/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
